Healthcare
China Everbright hits $115m first close on healthcare fund
China Everbright has completed the first close of RMB800 million ($115.4 million) on its third healthcare fund. The overall target for the vehicle is around RMB1.5 billion.
Kendall Court invests $55m in Indonesia hospital operator
Kendall Court has invested $55 million in Mandaya Medical, a healthcare-focused subsidiary of Indonesian conglomerate Selaras Group, via convertible preference shares.
SBI backs $18m round for Japan bio-robotics start-up
SBI Investment has joined a $17.7 million funding round for Meltin, a Japanese company focused on combining robotics with bio-signal processing.
Carlyle, Chinese strategic buy stake in clinical labs player Adicon
The Carlyle Group and Chinese healthcare services provider Meinian Onehealth have together invested in Adicon Holding, a local independent clinical laboratory (ICL) provider. Carlyle is now the company's single largest shareholder.
US-China biotech: Troubled transfers
Chinese investment in US biotech – and its ability to import intellectual property for domestic drug development – looks set to be a casualty of worsening relations between the two nations
Sequoia leads Series B for China's Deep Intelligent Pharma
Deep Intelligent Pharma (DIP) has raised $15 million in a Series B funding from Sequoia Capital China, with the proceeds to be used for accelerating the development of the company’s artificial intelligence (AI) powered drug discovery platform.
Wilmar Ventures backs Alzheimer's specialist Accera
Wilmar Ventures, an investment arm of Asian agribusiness conglomerate Wilmar International, has led a $50 million funding round for Accera, a developer of treatments for Alzheimer’s disease.
Riverside exits Australian orthopedics player
The Riverside Company has sold Australia’s Global Orthopaedic Technologies (GOT) for an undisclosed sum to Corin Orthopaedic, a UK-based firm recently bought by Permira.
Portfolio: Quadria Capital & Indonesia's Soho Global Health
Quadria Capital has brought the clarity and energy that venerable Indonesian pharmaceutical firm Soho Global Health needs as it addresses pent-up demand in Southeast Asia’s healthcare market
CLSA co-leads funding round for Taiwan's ACT
CLSA Capital Partners (CLSA CP) has co-led a funding round of undisclosed size for ACT Genomics, a Taiwan-based developer of genetic sequencing and diagnostic services.
Eight Roads leads Series C for India's PharmEasy
Indian online pharmacy PharmEasy has raised a $50 million Series C funding round led by Eight Roads Ventures, the proprietary investment arm of Fidelity International.
Deal focus: GA targets mass-market healthcare
General Atlantic has committed $150 million to Hong Kong Asia Medical Holdings, a Chinese hospital operator that stands out among private players in that it accepts payment through the national health insurance system
KKR creates China hospital platform
KKR has launched a China hospital management and investment platform – known as SinoCare Group – that will pursue a consolidation strategy in the space through a combination of acquisitions and new builds.
China's HighLight to exit US-based biotech player Bonti
Chinese healthcare-focused GP HighLight Capital is set to exit its position in US-based biotechnology company Bonti after Allergan agreed to acquire the business for $195 million, plus additional payments if certain development targets are met.
KKR to buy Life Healthcare stake in India hospital JV
KKR has agreed to pay INR4.3 billion ($59.6 million) to South African hospital chain Life Healthcare Group for its stake in Max Healthcare, a hospital operator that it owns through a joint venture with Max India.
PE-backed WuXi AppTec targets Hong Kong listing
Wuxi AppTec, a contract pharmaceutical R&D services provider backed by several private equity investors, has filed for a Hong Kong listing less than four months after listing in Shanghai. The size and pricing of the IPO have yet to be decided, but the...
Hong Kong Asia Medical receives $150m from General Atlantic
Hong Kong Asia Medical, a privately-owned Chinese cardiology hospital operator, has received a $150 million investment from General Atlantic amid escalating interest from global investors toward China’s biotech and healthcare industry.
OPIC commits $150m to Quadria healthcare fund
The Overseas Private Investment Corporation (OPIC), a development finance arm of the US government, has committed $150 million to Quadria Capital II, the latest fund of healthcare-focused PE firm Quadria Capital.
Deal focus: GTJA targets China online pharmacy boom
Healthcare specialist GTJA Investment Group leads a $130 million Series B for Jianke in the expectation that the company will consolidate its leadership position in China's online pharmacy market
China healthcare big data platform gets $30m Series B
Weimai, a Chinese healthcare-focused big data platform that operates on a city-by-city basis, has received $30 million in Series B funding led by Cenova Ventures, Source Code Capital, Vision Plus Capital, and Matrix Partners China.
China Renaissance set for wealth management push
China Renaissance Holdings is planning an aggressive push into wealth management services, targeting high net worth individuals in China’s new economy, with proceeds from its upcoming Hong Kong IPO.
PE-backed Chinese online pharmacy completes $100m US IPO
Chinese online pharmacy operator 111 Inc – best known for its 1 Drugsstore platform – traded down slightly on its NASDAQ debut after raising $100.5 million in a scaled back IPO.
Carlyle invests in Chinese pharma industry supplier
The Carlyle Group has paid an undisclosed sum for a significant minority stake in Ambio, a US-based pharmaceuticals company with substantial operations in China.
China's Jianke raises $130m Series B
Chinese online pharmacy operator Jianke has closed a $130 million Series B funding round led by healthcare-focused GTJA Investment Group.